US 12,134,640 B2
Polypeptides and medical uses thereof
Matthias Mörgelin, Anderslöv (SE); and Suado Abdillahi, Armadale (AU)
Assigned to COLZYX AB, Lund (SE)
Filed by COLZYX AB, Lund (SE)
Filed on Oct. 9, 2023, as Appl. No. 18/483,108.
Application 16/839,155 is a division of application No. 16/066,912, granted, now 10,793,618, issued on Oct. 6, 2020, previously published as PCT/EP2017/051246, filed on Jan. 20, 2017.
Application 18/483,108 is a continuation of application No. 17/474,434, filed on Sep. 14, 2021, granted, now 11,814,422.
Application 17/474,434 is a continuation of application No. 16/839,155, filed on Apr. 3, 2020, granted, now 11,136,374, issued on Oct. 5, 2021.
Claims priority of application No. 1601136 (GB), filed on Jan. 21, 2016.
Prior Publication US 2024/0043500 A1, Feb. 8, 2024
Int. Cl. C07K 14/78 (2006.01); A01N 47/44 (2006.01); A61L 15/32 (2006.01); A61L 15/44 (2006.01); A61L 17/00 (2006.01); A61L 17/14 (2006.01); A61L 24/00 (2006.01); A61L 24/10 (2006.01); A61L 27/22 (2006.01); A61L 27/24 (2006.01); A61L 27/34 (2006.01); A61L 27/54 (2006.01); A61L 27/60 (2006.01); A61L 29/04 (2006.01); A61L 29/08 (2006.01); A61L 29/16 (2006.01); A61L 31/04 (2006.01); A61L 31/10 (2006.01); A61L 31/16 (2006.01); A61P 17/02 (2006.01); A61P 31/04 (2006.01); C07K 14/47 (2006.01); C07K 14/755 (2006.01); A61K 9/00 (2006.01); A61K 9/70 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/78 (2013.01) [A01N 47/44 (2013.01); A61L 15/32 (2013.01); A61L 15/325 (2013.01); A61L 15/44 (2013.01); A61L 17/005 (2013.01); A61L 17/145 (2013.01); A61L 24/0015 (2013.01); A61L 24/102 (2013.01); A61L 24/108 (2013.01); A61L 27/227 (2013.01); A61L 27/24 (2013.01); A61L 27/34 (2013.01); A61L 27/54 (2013.01); A61L 27/60 (2013.01); A61L 29/045 (2013.01); A61L 29/048 (2013.01); A61L 29/085 (2013.01); A61L 29/16 (2013.01); A61L 31/044 (2013.01); A61L 31/047 (2013.01); A61L 31/10 (2013.01); A61L 31/16 (2013.01); A61P 17/02 (2018.01); A61P 31/04 (2018.01); C07K 14/4723 (2013.01); C07K 14/755 (2013.01); A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 9/7023 (2013.01); A61K 38/00 (2013.01); A61L 2300/252 (2013.01); A61L 2300/404 (2013.01); A61L 2300/606 (2013.01); A61L 2420/00 (2013.01); A61L 2430/34 (2013.01); C07K 2319/00 (2013.01)] 19 Claims
 
1. A polypeptide comprising an amino acid sequence selected from the group consisting of:
(a) SEQ ID NO: 2 derived from the α3 chain of collagen type VI,
(b) a fragment of SEQ ID NO: 2, wherein the fragment of SEQ ID NO: 2 comprises at least 20 contiguous amino acids of SEQ ID NO: 2, and
(c) a variant of SEQ ID NO: 2, wherein the variant comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 2,
wherein the polypeptide is between 20 and 200 amino acids in length, and
wherein the polypeptide, fragment, or variant is capable of killing or attenuating the growth of microorganisms.